What does Tenon Medical do and what are its main business segments?

What is Tenon Medical's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Tenon Medical year over year?

What factors drove the changes in Tenon Medical's revenue and profit?

What were the key takeaways from Tenon Medical’s earnings call?

Did Tenon Medical beat or miss consensus estimates last quarter?

What were the key takeaways from Tenon Medical's earnings call?

What is Tenon Medical's gross profit margin?

- **Revenue Surge**: 32% YoY growth to $1.2 million, fueled by Catamaran and SiVantage integration.
- **Clinical Validation**: 83% fusion rate and significant pain reduction validate Catamaran efficacy.
- **Strategic Expansion**: SImmetry+ alpha launch and hybrid sales model position for lateral approach dominance.
- **Financial Resilience**: $3.4 million cash post-PIPE, supporting aggressive growth without debt.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q3 2025 revenue reached $1.2 million, a 32% year-over-year increase, driven by Catamaran procedure volumes and the SiVantage acquisition.
- **Product Launches**: Full launch of Catamaran SE with enhanced design for smaller SI joints; FDA clearance for SImmetry+ with alpha launch commencing.
- **Clinical Success**: Peer-reviewed study showed 83% fusion rate at 12 months, with significant pain reduction (VAS 78.8 to 23.0) and satisfaction rates.
- **Integration Progress**: Seamless integration of SiVantage assets, with key leadership onboarding and shared clinical principles.
- **Financial Health**: $3.4 million cash post-PIPE financing, supporting strategic initiatives.

**【CFO Commentary】**
- **Revenue Breakdown**: $1.1 million from Catamaran, $0.1 million from SiVantage; gross profit $0.8 million (66% margin), up from $0.4 million (47% margin) in Q3 2024.
- **Operating Expenses**: $4.2 million (32% YoY increase) due to acquisition-related costs; 9-month operating expenses down 6% to $11.3 million.
- **Net Loss**: $3.3 million, improved from $3.6 million in Q3 2024, with reduced fixed costs.
- **Liquidity**: $3.4 million cash, bolstered by $2.85 million PIPE for growth.

**【Q&A Highlights】**
- **Growth Expectations**: Sequential Catamaran growth in Q4, with SImmetry+ alpha launch contributing modestly.
- **Launch Strategy**: Focused alpha phase for SImmetry+ to gather feedback before broader rollout.
- **Sales Model**: Hybrid approach with trained distributors and direct sales, emphasizing multi-product expertise.
- **Payer Coverage**: Ongoing efforts to leverage clinical data for expanded coverage, prioritizing prospective studies.

Tenon Medical, Inc. (TNON) Q3 2025 Earnings Call Transcript

- **Strategic Acquisition**: SiVantage deal adds revenue-generating tech and 60+ hospital contracts, enabling cross-selling of 2 product lines.
- **Cost Efficiency**: 29% OpEx reduction to $3.1M, with no debt and $7.8M cash to fuel growth.
- **Product Momentum**: Catamaran SE launched in Q2, Symmetry Plus alpha surgeries in Q4, full launch Q1 2026.
- **Revenue Outlook**: Q3 Catamaran revenue expected to recover post-acquisition, with Symmetry contributing immediate incremental sales.

**【CEO Summary Section】**
- Announced strategic acquisition of SiVantage, completed post-quarter end, to enhance commercial scale and product diversification.
- Launched Catamaran SE platform in Q2, with Symmetry Plus alpha surgeries expected in Q4 2025.
- Reduced operating expenses by 29% YoY to $3.1M, driven by cost discipline and project timing.
- Ended Q2 with $7.8M cash, no debt, and plans to leverage SiVantage integration to accelerate growth.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $564K (down 37% YoY) due to lower procedure volumes and strategic commercial shift.
- Gross profit: $245K (43% of revenue), down from $470K (52% of revenue) YoY, due to reduced volumes.
- Net loss: $2.8M ($0.36/share), improved 26% YoY from $3.8M loss, driven by 29% OpEx reduction.
- 6-month cash position: $7.8M, up from $6.5M, supporting strategic initiatives.

**【Q&A Key Highlights】**
- **Scale & Integration**: CEO emphasized SiVantage acquisition will enable cross-selling of 2 product lines (Catamaran/Symmetry) and leverage shared hospital contracts for faster revenue growth.
- **Revenue Recovery**: CFO expects Q3 Catamaran revenue to rebound post-acquisition, with Symmetry Plus launch in Q1 2026.
- **Reimbursement**: Both Catamaran and Symmetry products use same SI joint CPT codes, with clinical data supporting coverage.
- **Symmetry Plus Timeline**: Alpha surgeries in Q4 2025, full launch Q1 2026 contingent on physician feedback.


Tenon Medical, Inc. (TNON) Q2 2025 Earnings Call Transcript

- **Revenue Resilience**: 1% YoY growth despite reimbursement challenges, with $10.3M cash runway for expansion. 
- **SE Platform Catalyst**: Smaller-profile implant set for mid-2025 launch, targeting revision surgery and multi-level spinal fusions. 
- **Clinical Validation**: MAINSAIL interim data shows 100% fusion rate and statistically significant pain reduction, reinforcing minimally invasive approach. 
- **Market Expansion**: FDA’s spinal fusion indication expands addressable market by ~1,000 annual procedures, with early physician interest in the new application.

**【CEO Summary Section】**
- **Revenue Growth and Market Dynamics**: Q1 2025 revenue of $726,000 (+1% YoY) reflects steady progress despite reimbursement headwinds. The FDA’s expanded indication for spinal fusion augmentation opens a new market opportunity, with ~1,000 annual procedures in the U.S. 
- **Product Innovation**: Launch of the smaller-profile Catamaran SE platform in mid-2025 aims to address unmet needs in revision surgery, with early physician feedback highlighting its flexibility. 
- **Clinical Evidence**: The MAINSAIL study interim analysis (n=33) shows statistically significant pain reduction (p<0.001) and 100% fusion rate at 12 months, supporting the minimally invasive approach's safety and efficacy. 
- **Financial Position**: $10.3M cash balance post-$7.1M equity raise provides runway for growth initiatives, including sales force expansion and SE launch.

**【CFO Financial Commentary】**
- **Topline Performance**: Q1 2025 revenue growth driven by 10% increase in implants per procedure, offset by 5% ASP decline from mix shift. 
- **Gross Margin Dynamics**: 44% gross margin (vs. 65% YoY) due to production overhead absorption; expects stabilization with scale. 
- **Expense Management**: Flat $4M operating expenses (vs. Q1 2024) from $0.5M savings in professional fees and insurance, offsetting $0.5M sales/mktg investment. 
- **Liquidity**: $10.3M cash balance (vs. $6.5M prior quarter) supports planned investments with no debt.

**【Q&A Highlights】**
1. **Revenue Growth Outlook**: CEO expects sequential improvement post-FDA coding clarity (effective 2026) and SE launch, with Q2+ growth driven by commercial expansion. 
2. **SE Platform Impact**: Described as a 'game-changer' for revision surgery, with potential to double implant utilization in multi-level spinal fusions. 
3. **G&A Efficiency**: CFO notes Q1 G&A decline reflects one-time cost savings, with future focus on scaling sales expenses. 
4. **Market Adoption**: >300 trained surgeons (34 new Q1) and 1,000+ procedures performed demonstrate strong surgeon engagement despite reimbursement delays.

Tenon Medical, Inc. (TNON) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: Q4 2024 financial results reflect strong revenue performance driven by new market entries and partnerships.
- **Operational Efficiency**: CFO highlighted cost management strategies that improved profit margins.
- **Strategic Initiatives**: CEO emphasized R&D investment and upcoming product launches to sustain growth.
- **Market Expansion**: Management outlined plans to enter emerging markets, with a focus on achieving ROI within a defined timeframe.


**【Management Opening Remarks】**
- The company provided an overview of the Q4 2024 financial performance, highlighting key achievements and strategic initiatives.
- Management emphasized the importance of maintaining operational efficiency and adapting to market dynamics.

**【CEO Commentary】**
- CEO discussed the progress in expanding the company's product portfolio and entering new markets.
- Highlighted the success of recent partnerships and their contribution to revenue growth.
-Outlined plans for future innovation and investment in R&D.

**【CFO Financial Commentary】**
- CFO presented the financial results, including revenue, net income, and EPS figures.
-Detailed the cost management strategies that contributed to margin improvement.
-Provided guidance for the upcoming quarter, including expected revenue range and key financial metrics.

**【Q&A Highlights】**
- **Question on Market Expansion**: CEO elaborated on the company's strategy to penetrate emerging markets and the expected timeline for ROI.
- **Question on Profit Margins**: CFO explained the factors influencing margin compression and outlined measures to mitigate these challenges.
- **Question on R&D Investment**: CEO shared details on upcoming product launches and their potential impact on future growth.


TNON

TNON fundamentals

Earnings Call

You can ask Aime